Focus: VBI Vaccines is a Cambridge-based mid-cap biotech focused on vaccine development for infectious diseases, with ~1,000–5,000 employees and an active pipeline spanning hepatitis B, COVID-19, CMV, and oncology indications.
Profile data last refreshed 9h ago · AI intelligence enriched 1w ago
Stable — net +3 jobs in 30d
3 added, 0 removed. Backfill posture.
VBI represents a mid-stage vaccine biotech with meaningful pipeline depth, but limited hiring activity and opaque financials warrant caution on career velocity and runway stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for VBI Vaccines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from VBI Vaccines's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo